Front-line employee self-determination in value Co-Creation: Generational profiles
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Hospitality and Tourism Management"
DOI: 10.1016/j.jhtm.2021.08.004
Abstract: Abstract Hospitality value co-creation studies have generally focused on the customer. However, service-dominant logic postulates that all actors must benefit from successful value co-creation. In this study, the employee self-determination factors of autonomy, competence, and… read more here.
Keywords: creation; self determination; employee self; value creation ... See more keywords
Ultra-rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T2D at Multiple Meal-to-Dose Timing Intervals
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1009-p
Abstract: URLi (LY900014), a novel ultra-rapid mealtime insulin in Phase 3 development, is shown to reduce postprandial glucose after subcutaneous injection. This 2-part, randomized, double-blind, Phase 1b study evaluated differences in PK and PD between URLi… read more here.
Keywords: eli lilly; lilly company; employee self; self eli ... See more keywords
Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study, Primary Population
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1011-p
Abstract: VIVID is the first prospective, randomized controlled trial to assess efficacy and safety of U-500R (Humulin® R U-500) administered by CSII (using an investigational Omnipod U-500™ Insulin Management System) vs. MDI (TID). This 26-week, open-label,… read more here.
Keywords: insulin; lilly company; eli lilly; employee self ... See more keywords
Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1067-p
Abstract: MEDI0382 is under development for the treatment of type 2 diabetes mellitus (T2DM). In a double-blind study (NCT02548585), 51 T2DM patients with BMI 27-40 kg/m 2 were randomized (1:1) to daily SC MEDI0382 200 μg… read more here.
Keywords: employee; self astrazeneca; self; employee self ... See more keywords
OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1118-p
Abstract: Activation of glucagon-like peptide-1 receptors (GLP-1R) is a promising approach for the treatment of type 2 diabetes mellitus (T2D), and several peptide analogues of GLP-1 have been successfully developed. Here we identified a new orally… read more here.
Keywords: chugai pharmaceutical; glp; self chugai; pharmaceutical ltd ... See more keywords
Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1129-p
Abstract: This Phase 3 randomized, double-blind study in adults with T2DM (A1C 7.0-10.5%) on MET monotherapy (≥1500 mg/day ≥8 weeks) included a 26 week placebo (PBO)-controlled period followed by a 78 week extension where non-rescued PBO… read more here.
Keywords: week; ertu; pfizer inc; employee self ... See more keywords
Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1135-p
Abstract: Semaglutide is a glucagon-like peptide (GLP-1) analog co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), to allow oral administration. The effect of oral semaglutide on the pharmacokinetics (PK) of the combined oral contraceptive… read more here.
Keywords: self novo; employee self; oral semaglutide; novo nordisk ... See more keywords
Discovery and Development of HGR4113 as a Novel Antidiabetes Oral Agent
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1158-p
Abstract: HGR4113 is a novel compound that was discovered by Glaceum Inc. through a Quantitative Structure-Activity Relationship (QSAR) study on Glabridin and its derivatives. HGR4113 showed competitive antihyperglycemic effects in db/db mice without any adverse event… read more here.
Keywords: self glaceum; hgr4113 novel; hgr4113; employee self ... See more keywords
HERV-W-Env Involvement in Human T1D Pathogenesis—New Insights from Two Mouse Models
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-160-lb
Abstract: Human endogenous retroviruses (HERVs), known to represent 8% of the human genome, have been associated with several autoimmune diseases. In particular, the envelope protein of HERV-W family (HERV-W-Env), which has been involved in the pathogenesis… read more here.
Keywords: mouse models; herv env; human t1d; self geneuro ... See more keywords
Conformance to Type 2 Diabetes (T2D) Guidelines in a Large U.S. Health Plan
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1658-p
Abstract: Almost half of U.S. T2D patients (pts) have suboptimal glycemic control (A1c ≥7%). One factor that may be associated with this is clinical inertia related to physician/patient actions or lack of “conformance” to guidelines. We… read more here.
Keywords: conformance; self merck; conformance type; merck inc ... See more keywords
MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1841-p
Abstract: Nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis, inflammation and fibrosis is an unmet medical need. MEDI0382, a balanced GLP-1/glucagon dual receptor agonist, is under development for the treatment of T2DM. Here we examined the effects… read more here.
Keywords: glp glucagon; self astrazeneca; self; medi0382 ... See more keywords